Multi-centre validation tests AI-empowered OncoSeek across 15,122 participants and four assay platforms
A 2025 study added four cohorts to evaluate the seven-protein-marker OncoSeek test, which combines blood protein tumor markers and clinical variables with AI. Across seven cohorts from seven centres in China, Brazil and the United States, totaling 15,122 participants, the reported overall sensitivity was 58.4% at 92.0% specificity; the symptomatic cohort had 73.1% sensitivity at 90.6% specificity. The study also tested performance across four platforms and two sample types.
Technology: OncoSeek AI-empowered blood test combining seven protein tumor markers with individual clinical data
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: A 2025 study added four cohorts to evaluate the seven-protein-marker OncoSeek test, which combines blood protein tumor markers and clinical variables with AI.
- Still unknown: This is a retrospective/observational cohort validation of a blood test, not evidence that screening improves outcomes or reduces mortality. Aggregate sensitivity was 58.4% and performance varied by cancer type; several cancer-specific groups were small. The article adds validation to a previously published OncoSeek test, so this record is limited to the new expanded-cohort/platform result, not a claim of first test discovery.
- AI role: The AI-assisted test integrated measured protein-marker values and clinical variables for multicancer classification. This paper evaluated its performance in four additional validation cohorts, including a prospective blinded study and symptomatic case-control cohort, and aggregated results across seven cohorts.
Evidence sources: https://www.nature.com/articles/s41698-025-01105-2.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 78 of works of the same type, year and subfield (OpenAlex work metrics, 5 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.